Which biotech’s shares have hit a 12-month high on good news from the FDA?

Shareholders in Neuren Pharmaceuticals Ltd (ASX: NEU) are rejoicing after one of the company’s drugs, which shows promise in treating a rare genetic disorder, received fast-track designation from the US Food & Drug Administration (FDA).

Neuren told the ASX in a…